This Solicitation opportunity from Department Of Health And Human Services was posted on August 12, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections

Closed

75A50125R00002Federal

Submission Closed08/26/2025, 04:00:00 AM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 541714

New

Federal

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

POSTED

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

POSTED

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

POSTED

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics

Solicitation # PROC-9177507

The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.

Grains Research and Development Corporation

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

The US Army Combat Capabilities Development Command Soldier Center is seeking information from Massachusetts-based offerors to identify innovative alternative protein technologies for integration into military rations. The objective is to enhance food supply chain resilience and provide nutrient-dense, lightweight food options for warfighters. Areas of interest include fermentation and biomanufacturing processes, innovative product development for shelf-stable rations, consumer research for military acceptability, and the optional provision of GRAS-certified food samples. Specifically, the government is excluding any solutions involving cell-cultured, lab-grown meat, or insect proteins, focusing instead on technologies between TRL 4 and 6. This is a Sources Sought Announcement for market research purposes and not a formal solicitation or a promise of future funding. Interested parties must submit a BAA preproposal by November 23, 2026, including a technical approach, past performance, and a rough order of magnitude cost estimate. Submissions must be sent via email to the designated points of contact and include the offeror's business size, NAICS code, and CAGE code to verify their Massachusetts location.

W6QK Acc-Apg Natick

POSTED

2 days ago

DEADLINE

in about 1 month

AI Contract Overview

BARDA is seeking qualified vendors to support the advanced development, procurement, and stockpiling of antibiotics targeting hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), bloodstream infections (BSI), and potential biothreat pathogens. The focus is on antibiotics that have already demonstrated progress by holding end-of-Phase 2 meetings with the FDA for HABP/VABP or BSI indications, or those approved for these conditions with sufficient data to expand into biothreat applications. Vendors must provide comprehensive services, including qualified personnel, materials, and facilities, with an emphasis on domestic manufacturing capabilities or a clear plan to establish onshore drug substance production and fill/finish processes. The contract duration is up to 120 months, with an anticipated award date between September 30, 2025, and September 30, 2026, and work may be performed at the vendor’s facilities or through subcontractors such as research organizations or manufacturing firms. This effort is integral to BARDA’s preparedness strategy, ensuring the availability of critical antibiotics for resistant bacterial infections and biothreat scenarios. It excludes the use of Federal Supply Schedules or Government Wide Acquisition contracts, requiring all respondents to be registered in the System for Award Management (SAM). The solicitation, titled "Antibiotic for Treatment of Bacterial Pneumonia or Bloodstream Infections," is open until August 26, 2025, and is managed by the Department of Health and Human Services in Washington, D.C. Interested vendors can contact the designated contracting officers for further details and must demonstrate existing or planned domestic manufacturing capabilities aligned with the project’s objectives.

General Info

BARDA seeks vendors for antibiotic development, domestic manufacturing, and stockpiling for biothreats.

Agency

Department Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Washington, DC, USA

Set-Aside

NONE

Documents

75A50125R00005 Amendment 0001

amendment

High

75A50125R00005 Amendment 0002

6 pages · amendment

High

75A50125R00005 Amendment 0004

2 pages · amendment

High

Solicitation 75A50125R00005 Amendment 0003

amendment

High

Solicitation 75A50125R00005 - PBS AMR 2025

85 pages · rfp

High

Solicitation 75A50125R00005 - PBS AMR 2025 Amendment 2

84 pages · rfp

High

Solicitation 75A50125R00005 - PBS AMR 2025 Amendment 3

84 pages · rfp

High

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

4 updates

PhaseClosed

PostedJul 13

Solicitation

Notice updatedJul 14

The notice description changed.

Notice updatedJul 30

Notice details unchanged. Attachments may have changed.

Notice updatedAug 4

The notice description changed.

Deadline changedAug 12

Response deadline time changed from 4:00 PM UTC to 4:00 AM UTC on Aug 26, 2025.

Response DeadlineAug 26

Deadline has passed

Submission Closed

08/26/2025, 04:00:00 AM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Contacts2 people available

OfficeWASHINGTON, DC, 20515, USA

Organization / AgencyDepartment Of Health And Human Services → Barda - Aspr / Daappo / Barda Dcma

Office AddressWASHINGTON, DC, 20515, USA

Contacts

Erin Greninger Contracting Officer

contact@example.gov

Audrey Glover

contact@example.gov

Full Description

BARDA seeks to identify qualified vendors capable of advancing the development of antibiotics for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI), as well as post-exposure prophylaxis (PEP) and/or treatment of biothreat pathogens. In direct support of BARDA's preparedness and response posture, the antibiotics will be positioned for potential procurement. Capable vendors must furnish all necessary services, qualified professional, technical and administrative personnel, materials, equipment, and facilities to perform the required tasks. The target product description and mandatory source requirements are antibiotic programs that 1) already have held their end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), with an intended indication for the treatment of HABP/VABP; 2) or already have held their end-of-Phase 2 meeting with the FDA, with an intended indication for the treatment of BSI; 3) or already have held their end-of-Phase 2 meeting with the FDA, with an intended indication for the treatment of HABP/VABP or BSI that could also be developed for a biothreat indication; 4) or antibiotics that are approved for HABP/VABP and/or BSI that have sufficient data to warrant development for a biothreat indication. This project is for investing in late-stage development, procurement, and stockpiling of antibiotics to treat HABP/VABP and/or BSI caused by drug-resistant bacterial and/or biothreat pathogens, and actively seeks vendors with existing domestic manufacturing capabilities or at minimum a timeline and summarized approach to onshore drug substance manufacturing and fill/finish of drug product. The total period of performance will be no more than 120 months; the period of performance for the Base and Option periods may overlap; the duration of each period will be dependent on the work proposed. Contract(s) expected to be executed September 30, 2025-September 30, 2026. The work will be performed at the responder's facilities or subcontracted out to commercial laboratories, contract research organizations, and/or contract manufacturing organizations. Unique requirements include domestic drug substance and fill/finish drug product manufacturing, implemented or a timeline and summary of the approach to onshore manufacturing. Federal Supply Schedules and Government Wide Acquisition contracts are not available to purchase this service. Currently, there are no identified related requirements that will affect this service and conversely, this service will not affect other requirements. All respondents must be registered in the System for Award Management (SAM): https://www.sam.gov.